









Markets
/
Stocks
/
nasdaq-cers
/

Cerus Corp

CERS

2.200USD

+0.060+2.80%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

422.48MMarket Cap

LossP/E TTM



Cerus Corp

2.200

+0.060+2.80%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cerus Corp

Currency: USD Updated: 2026-02-06

Key Insights

Cerus Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 81 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.67.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cerus Corp's Score

Industry at a Glance

Industry Ranking

81 / 205

Overall Ranking

220 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Cerus Corp Highlights

StrengthsRisks

Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.

Undervalued

The company’s latest PE is -26.14, at a low 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 182.24K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.667

Target Price

+118.07%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cerus Corp is 6.54, ranking 148 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 60.24M, representing a year-over-year increase of 18.91%, while its net profit experienced a year-over-year increase of 99.35%.

Score

Industry at a Glance

Previous score

6.54

Change



Financials

5.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.56

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.39

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.35

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cerus Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cerus Corp is 7.27, ranking 100 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -26.14, which is -82.79% below the recent high of -4.50 and -24.55% above the recent low of -32.55.

Score

Industry at a Glance

Previous score

7.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 81/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cerus Corp is 7.50, ranking 129 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 5.00, with a high of 5.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.667

Target Price

+118.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Cerus Corp

CERS

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cerus Corp is 6.96, ranking 65 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.78 and the support level at 1.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.87

Change

0.09

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.104

Neutral

RSI(14)

45.123

Neutral

STOCH(KDJ)(9,3,3)

15.322

Oversold

ATR(14)

0.140

Low Volatility

CCI(14)

-131.008

Sell

Williams %R

85.987

Oversold

TRIX(12,20)

0.280

Sell

StochRSI(14)

34.905

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

2.258

Sell

MA10

2.325

Sell

MA20

2.415

Sell

MA50

2.174

Buy

MA100

1.854

Buy

MA200

1.594

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cerus Corp is 7.00, ranking 80 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 74.92%, representing a quarter-over-quarter decrease of 1.95%. The largest institutional shareholder is Catherine Wood, holding a total of 18.85M shares, representing 9.81% of shares outstanding, with 9.18% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

18.85M

-1.86%

BlackRock Institutional Trust Company, N.A.

15.58M

+0.98%

The Vanguard Group, Inc.

Star Investors

10.78M

+0.58%

Baker Bros. Advisors LP

10.01M

-22.32%

Wasatch Global Investors Inc

Star Investors

5.54M

-35.09%

Amova Asset Management Co., Ltd.

5.69M

-6.34%

Geode Capital Management, L.L.C.

4.52M

+3.99%

BlackRock Financial Management, Inc.

4.26M

+2.41%

Silvercrest Asset Management Group LLC

4.12M

+18.29%

Senvest Management, LLC

3.97M

-1.01%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cerus Corp is 3.99, ranking 115 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.